Associate Professor of the Department of Public Health Sciences
University of Miami Miller School of Medicine
She is currently serving as the Director of Public Health Education and as a director of the Americas Initiative for Public Health Innovation. She is also the Executive director of the Florida Node Alliance of the National Drug Abuse Treatment Clinical Trials Network (CTN) housed at the University of Miami. The Florida Node Alliance is a partnership between is scientists and program leaders at the University of Miami with scientist and practice leaders from community treatment agencies located in Florida, Colorado, and Puerto Rico. As partners, scientists and practitioners design, implement and train in interventions for substance abuse treatment. Dr. Horigian has contributed to the design and implementation of the trials led by the Florida Node Alliance manages its day-to-day operations and has more than 17 years of experience in the implementation of multi-site randomized clinical trials in real world settings with the final goal of improving clinical practice. Dr. Horigian’s research career has been committed to creating the local capacities that would allow the implementation of such trials. As such, she was the Principal Investigator of a technology transfer project that aimed to develop the research infrastructure for the implementation of rigorous randomized clinical trials for substance abuse and mental health in Mexico. In this role, she mentored investigators from the National Institute of Psychiatry in Mexico on the design, implementation, safety, and interpretation of the results of RCTs in real-world treatment settings. She has used the same methodology for technology transfer to develop research capacity in Ecuador and Chile. Due to her international leadership, she was honored with the 2015 National Institute on Drug Abuse (NIDA) International Program Award of Excellence.
Currently, she is also the Site principal Investigator for two clinical trials testing intervention to tackle the Opioid Epidemic, one focused on testing a strategy that will facilitate the integration of medication treatment for opioid use disorders in primary care, and a trial that will test two different formulations of buprenorphine in pregnant women, and will follow their newborns overtime.